invest1 distinct publisher
JW Pharmaceutical bets a two-indication Phase 3 on halving GLP-1 injections to 26 a year
The in-licensed candidate bofanglutide enters late-stage trials in obesity and type 2 diabetes covering 474 Korean patients, both against placebo, so the biweekly dosing that justifies the spend never meets a weekly rival.
Publishers:en.sedaily.com
Reality
- Evidence33
- Adoption9
- Hype gap+27
- Incentives71